Vitamin D and Disease Severity in Multiple Sclerosis-Baseline Data From the Randomized Controlled Trial (EVIDIMS)

Area of Science:

• Neurology
• Endocrinology
• Immunology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Vitamin D deficiency is common in MS patients and may influence disease activity.
• Understanding the relationship between vitamin D and MS progression is crucial for treatment strategies.

Purpose of the Study:

• To examine the link between vitamin D levels and disease activity in relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) patients.
• To determine if hypovitaminosis D is associated with clinical and MRI-defined disease markers.
• To evaluate the impact of vitamin D status on disease progression in MS.

Main Methods:

• A cohort of 53 RRMS and CIS patients on interferon-beta-1b treatment were analyzed.
• Serum 25-hydroxyvitamin D (25(OH)D) levels were measured at baseline.
• Patients were categorized into vitamin D deficient (<30 ng/ml) and sufficient (≥30 ng/ml) groups.

Main Results:

• 91% of patients exhibited vitamin D deficiency (25(OH)D < 30 ng/ml).
• Patients with sufficient vitamin D levels had significantly lower T2-weighted lesion counts on MRI.
• Higher serum 25(OH)D levels were associated with lower Expanded Disability Status Scale (EDSS) scores, independent of age, gender, and disease duration.

Conclusions:

• The majority of MS and CIS patients in this cohort were vitamin D deficient.
• Adequate vitamin D levels are associated with reduced MRI-detected disease activity and lower clinical disability in MS.
• These findings support the investigation of vitamin D supplementation as an adjunct therapy in MS management.